Liminal BioSciences Inc. PFSCF

Primary Symbol: LMNL

Healthcare Biotechnology

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.

NDAQ:LMNL - Post by User

Liminal BioSciences Inc.

Bullboard Posts

Comment by aldo451on Apr 19, 2019 6:09pm

76 Views

Post# 29649816

RE:RE:RE:Status Quo is not an option.

I agree that you keep the number of shares you currently own before the financing but what do you mean; your average cost will remain the same? What average are you referring to?

CCAbbott888 wrote:

wyndewest wrote: Martin, Just to be clear... in Example 1: you say if you do nothing after the rights offering you will still have 100,000 shares?? I thought you would have to buy back those 100,000 x.0152 to get 100,000 new shares. In other words if you do nothing the old shares will nolonger be valid (expire) and since you did nothing you won't have any new shares. Thanks for a reply.

Your shares do not expire. If you do nothing (i.e. do not participate in the rights offer), your share counts remain the same, the average cost remain the same as before the re-financing. At some points, the company will do a reverse split, which will drastically reduce your share count. For example, if they do a 1000:1 R/S, your 100,000 shares will become 100 shares.